Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Subjects With Cystic Fibrosis (CF)

This study will evaluate the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on cough and physical activity using wearable technology in CF participants.

tezacaftor
elexacaftor
ivacaftor
forced expiratory volume
fibrosis
  • 0 views
  • 17 Mar, 2022
  • 16 locations
Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy (SIMPLIFY)

Trikafta™. Trikafta (elexacaftor/tezacaftor/ivacaftor) is a combination CFTR modulator therapy that was approved by the Food and Drug Administration for people with CF who have at least one F508del

cystic fibrosis transmembrane conductance regulator
elexacaftor
dnase
pulmonary function test
dornase alfa
  • 65 views
  • 02 May, 2022
  • 78 locations
Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor

This is a prospective, single-center, fixed-sequence, nonrandomized, open-label study in healthy adults to investigate the impact of rifabutin on the pharmacokinetics of trikafta.

  • 0 views
  • 01 Oct, 2021
  • 1 location
Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER) (RECOVER)

RECOVER is a prospective, multicenter observational study designed to measure the real world clinical effectiveness of elexacaftor, tezacaftor and ivacaftor triple combination therapy (Kaftrio

tezacaftor
elexacaftor
spirometry
ivacaftor
fibrosis
  • 52 views
  • 18 May, 2022
  • 7 locations
Trikafta in Cystic Fibrosis Patients

This clinical study will enroll 42 participants without the F508del mutation, carrying partial function or N1303K mutations not approved for Trikafta, and who are not expected to be approved for CFTR modulator treatment in the immediate future. Each participant will be given Trikafta for approximately four weeks. The study researchers …

bronchiectasis
nasal potential difference
elexacaftor
pancreatic enzyme
pulmonary disease
  • 8 views
  • 27 Apr, 2022
  • 3 locations
Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials (Nof1)

The purpose of this study is to validate and utilize a personalized medicine approach to identify potential treatments with current FDA approved CFTR modifiers for non-approved CF gene mutations. The study will perform ex vivo testing of CFTR function and current marketed CFTR modulating drugs on expanded nasal cells at …

  • 0 views
  • 18 May, 2022
  • 1 location
Home-Reported Outcomes in People With Cystic Fibrosis Taking Highly Effective CFTR Modulator Therapy

This is an observational cohort study, using data from Folia Health and the Cystic Fibrosis Foundation Patient Registry (CFFPR). Individuals taking elexacaftor/tezacaftor/ivacaftor (ETI) may be

elexacaftor
tezacaftor
ivacaftor
fibrosis
  • 0 views
  • 22 Sep, 2021
  • 1 location
Impact of Triple Combination CFTR Therapy on Sinus Disease.

The study's main goal is to observe how effective elexacaftor-tezacaftor-ivacaftor is for improving the symptoms and signs of CF-related sinus disease.

  • 0 views
  • 19 Mar, 2021
  • 1 location
The PROMISE Pediatric Study 6 to 11 Years Old

This is a prospective, multi-center observational study. The study is designed to measure the clinical effectiveness of elexacaftor, tezacaftor and ivacaftor (ETI) triple combination therapy in

elexacaftor
tezacaftor
ivacaftor
fibrosis
  • 0 views
  • 04 May, 2022
  • 20 locations
Pulmonary Vascular Disease in CF

In this project, the investigators seek to understand the role of endothelial cells in Cystic Fibrosis (CF) lung disease. This objective will be achieved by conducting a cross sectional clinical study to define the morphology of the pulmonary circulation across a range of lung function coupled with a mechanistic study …

solid tumor
fibrosis
  • 0 views
  • 19 Nov, 2021
  • 2 locations